Cancer Immunotherapy May Weaken Bones in Melanoma Survivors

This clinical trial examined whether immunotherapy drugs commonly used to treat melanoma might cause bone density loss in cancer survivors. The research focused on nivolumab and pembrolizumab, two immune checkpoint inhibitors that boost the body's natural cancer-fighting abilities and are widely prescribed to prevent melanoma recurrence.

The study design involved collecting biospecimens and performing dual X-ray absorptiometry (DXA) scans to measure bone density changes in melanoma patients. Researchers also analyzed blood markers that indicate bone turnover rates, which can reveal early signs of bone loss before it becomes detectable on scans.

Unfortunately, the trial was terminated early after enrolling only 12 participants out of the planned cohort. The study was designed to run from May 2021 through June 2025, but recruitment challenges or other factors led to premature closure. Participants had stage III or IV melanoma according to current medical staging criteria.

Despite the limited enrollment, this research addresses a critical gap in understanding immunotherapy's long-term effects. Cancer immunotherapy has revolutionized melanoma treatment, dramatically improving survival rates. However, these powerful drugs can sometimes cause immune-related side effects by overstimulating the immune system.

The potential connection between immunotherapy and bone health has important implications for cancer survivors' long-term wellness. Bone loss increases fracture risk and can significantly impact quality of life, especially as patients age. If immunotherapy does affect bone density, early identification could enable preventive interventions like calcium supplementation, vitamin D optimization, or bone-strengthening medications to protect patients' skeletal health throughout their cancer journey and beyond.